{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:24:29Z","timestamp":1777134269615,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"DOI":"10.7759\/cureus.92598","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:58:11Z","timestamp":1758178691000},"source":"Crossref","is-referenced-by-count":1,"title":["In Thickness and in Health: Delayed-Onset Pompe Disease Resembling Hypertrophic Cardiomyopathy"],"prefix":"10.7759","author":[{"given":"Glenmore","family":"Lasam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Kristina Cassandra","family":"Lasam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems MG","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP, et al.. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999, 7:713-6. 10.1038\/sj.ejhg.5200367","journal-title":"Eur J Hum Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna S","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, et al.. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020, 12:15856-74. 10.18632\/aging.103794","journal-title":"Aging (Albany NY)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben N","year":"2002","unstructured":"Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med. 2002, 2:145-66. 10.2174\/1566524024605789","journal-title":"Curr Mol Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-8966(02)00186-4","article-title":"Effect of acid maltase deficiency on the endosomal\/lysosomal system and glucose transporter 4","volume":"13","author":"Orth M","year":"2003","unstructured":"Orth M, Mundegar RR. Effect of acid maltase deficiency on the endosomal\/lysosomal system and glucose transporter 4. Neuromuscul Disord. 2003, 13:49-54. 10.1016\/s0960-8966(02)00186-4","journal-title":"Neuromuscul Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160C","author":"Kroos M","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet. 2012, 160C:59-68. 10.1002\/ajmg.c.31318","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000217781.66786.9b","article-title":"Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease","volume":"8","author":"Zhang H","year":"2006","unstructured":"Zhang H, Kallwass H, Young SP, et al.. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006, 8:302-6. 10.1097\/01.gim.0000217781.66786.9b","journal-title":"Genet Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.09.006","article-title":"Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting","volume":"93","author":"Winchester B","year":"2008","unstructured":"Winchester B, Bali D, Bodamer OA, et al.. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab. 2008, 93:275-81. 10.1016\/j.ymgme.2007.09.006","journal-title":"Mol Genet Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x20130022","article-title":"Muscle biopsy in Pompe disease","volume":"71","author":"Werneck LC","year":"2013","unstructured":"Werneck LC, Lorenzoni PJ, Kay CS, Scola RH. Muscle biopsy in Pompe disease. Arq Neuropsiquiatr. 2013, 71:284-9. 10.1590\/0004-282x20130022","journal-title":"Arq Neuropsiquiatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani PS","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006, 148:671-6. 10.1016\/j.jpeds.2005.11.033","journal-title":"J Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/93.3.599","article-title":"Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies","volume":"93","author":"Engel AG","year":"1970","unstructured":"Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain. 1970, 93:599-616. 10.1093\/brain\/93.3.599","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans ML","year":"2005","unstructured":"Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005, 64:2139-41. 10.1212\/01.WNL.0000165979.46537.56","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: a comprehensive overview","volume":"7","author":"Peruzzo P","year":"2019","unstructured":"Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019, 7:278. 10.21037\/atm.2019.04.13","journal-title":"Ann Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.043","article-title":"A case of adult-onset Pompe disease with cerebral stroke and left ventricular hypertrophy","volume":"27","author":"Hossain MA","year":"2018","unstructured":"Hossain MA, Miyajima T, Akiyama K, Eto Y. A case of adult-onset Pompe disease with cerebral stroke and left ventricular hypertrophy. J Stroke Cerebrovasc Dis. 2018, 27:3046-52. 10.1016\/j.jstrokecerebrovasdis.2018.06.043","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy","volume":"13","author":"Forsha D","year":"2011","unstructured":"Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med. 2011, 13:625-31. 10.1097\/GIM.0b013e3182142966","journal-title":"Genet Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani PS","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, et al.. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009, 66:329-35. 10.1203\/PDR.0b013e3181b24e94","journal-title":"Pediatr Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-008-1000-0","article-title":"Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results","volume":"31 Suppl 2","author":"Hamdan MA","year":"2008","unstructured":"Hamdan MA, Almalik MH, Mirghani HM. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results. J Inherit Metab Dis. 2008, 31 Suppl 2:S431-6. 10.1007\/s10545-008-1000-0","journal-title":"J Inherit Metab Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12027","article-title":"The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review","volume":"42","author":"Milverton J","year":"2019","unstructured":"Milverton J, Newton S, Merlin T. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis. 2019, 42:57-65. 10.1002\/jimd.12027","journal-title":"J Inherit Metab Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel","volume":"180","author":"Maron BJ","year":"2022","unstructured":"Maron BJ, Dearani JA, Smedira NG, et al.. Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel. Am J Cardiol. 2022, 180:124-39. 10.1016\/j.amjcard.2022.06.007","journal-title":"Am J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto I","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al.. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020, 396:759-69. 10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.07.075","article-title":"Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010])","volume":"114","author":"Panaich SS","year":"2014","unstructured":"Panaich SS, Badheka AO, Chothani A, et al.. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). Am J Cardiol. 2014, 114:1390-5. 10.1016\/j.amjcard.2014.07.075","journal-title":"Am J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/405702-in-thickness-and-in-health-delayed-onset-pompe-disease-resembling-hypertrophic-cardiomyopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:58:12Z","timestamp":1758178692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/405702-in-thickness-and-in-health-delayed-onset-pompe-disease-resembling-hypertrophic-cardiomyopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.92598","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}